This study is testing a new medicine called KarXT to help people with Bipolar-I disorder who are having manic episodes. Bipolar-I disorder is a mental health condition where people have extreme mood swings, including mania, which is a very "up" or excited mood. The study is "double-blind," meaning neither the doctors nor the participants know who is getting the real medicine or a placebo (a sugar pill). The study lasts up to seven weeks, including a three-week stay in a hospital setting.
To join, you must currently experience mania or mixed features, which means some symptoms of mania and depression. You can't have other major psychiatric disorders or serious substance abuse problems. The study requires stopping other mental health medications for up to 14 days before starting the test medicine.
- Duration: Up to 7 weeks, including a 3-week hospital stay.
- Eligibility: Must have Bipolar-I disorder with current mania.
- Requirements: Must stop other medications before starting the study.